APA (7th ed.) Citation

De Novellis, D., Fontana, R., Palmieri, S., Della Pepa, R., Di Perna, M., Cetani, G., . . . Selleri, C. (2023). Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders. Targeted Oncology, 18(6), 885. https://doi.org/10.1007/s11523-023-01001-4

Chicago Style (17th ed.) Citation

De Novellis, Danilo, et al. "Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders." Targeted Oncology 18, no. 6 (2023): 885. https://doi.org/10.1007/s11523-023-01001-4.

MLA (9th ed.) Citation

De Novellis, Danilo, et al. "Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders." Targeted Oncology, vol. 18, no. 6, 2023, p. 885, https://doi.org/10.1007/s11523-023-01001-4.